Gerrit J.A. Vos

734 total citations · 1 hit paper
9 papers, 451 citations indexed

About

Gerrit J.A. Vos is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Gerrit J.A. Vos has authored 9 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 5 papers in Surgery and 4 papers in Internal Medicine. Recurrent topics in Gerrit J.A. Vos's work include Antiplatelet Therapy and Cardiovascular Diseases (8 papers), Acute Myocardial Infarction Research (4 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Gerrit J.A. Vos is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (8 papers), Acute Myocardial Infarction Research (4 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Gerrit J.A. Vos collaborates with scholars based in Netherlands, United Kingdom and Italy. Gerrit J.A. Vos's co-authors include Jurriën M. ten Berg, Folkert W. Asselbergs, Daniel M.F. Claassens, Thomas O. Bergmeijer, Vera H.M. Deneer, Paul W.A. Janssen, Willem J.M. Dewilde, Arnoud W.J. van ‘t Hof, Pim van der Harst and Arend Mosterd and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Heart Association and Catheterization and Cardiovascular Interventions.

In The Last Decade

Gerrit J.A. Vos

9 papers receiving 444 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gerrit J.A. Vos

Since Specialization

Citations

This map shows the geographic impact of Gerrit J.A. Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit J.A. Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit J.A. Vos more than expected).

Fields of papers citing papers by Gerrit J.A. Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit J.A. Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit J.A. Vos. The network helps show where Gerrit J.A. Vos may publish in the future.

Co-authorship network of co-authors of Gerrit J.A. Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Gerrit J.A. Vos. A scholar is included among the top collaborators of Gerrit J.A. Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerrit J.A. Vos. Gerrit J.A. Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Efficacy and safety of glycoproteinIIb/IIIainhibitors in addition toP2Y₁₂inhibitors inST‐segment elevation myocardial infarction: A subanalysis of thePOPularGenetics trial 2021 ·Catheterization and Cardiovascular Interventions ·(unknown), Daniel M.F. Claassens, Renicus S. Hermanides, Gerrit J.A. Vos, Thomas O. Bergmeijer, Johannes C. Kelder, Vera H.M. Deneer, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg	4
2	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype 2021 ·Circulation Cardiovascular Interventions ·Daniel M.F. Claassens, Thomas O. Bergmeijer, Gerrit J.A. Vos, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Bakhtawar K. Mahmoodi, Vera H.M. Deneer, Jurriën M. ten Berg	17
3	Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis 2021 ·Journal of the American Heart Association ·Bakhtawar K. Mahmoodi, Niclas Eriksson, Gerrit J.A. Vos, Karina Meijer, Agneta Siegbahn, Stefan James, Lars Wallentin, Jurriën M. ten Berg	3
4	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial 2021 ·American Journal of Cardiovascular Drugs ·Daniel M.F. Claassens, (unknown), Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Maarten J. Postma, Vera H.M. Deneer, Jurriën M. ten Berg, Cornelis Boersma	16
5	Effect of CYP3A422 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention 2020 ·Genes* ·Thomas O. Bergmeijer, (unknown), Gerrit J.A. Vos, Paul W.A. Janssen, Christian M. Hackeng, Johannes C. Kelder, Shefali S. Verma, Marylyn D. Ritchie, Li Gong, Teri E. Klein, (unknown), Anthonius de Boer, Olaf H. Klungel, Jurriën M. ten Berg, Vera H.M. Deneer	1
6	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI breakdown → 2019 ·New England Journal of Medicine ·Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Maarten J. Postma, Anthonius de Boer, Cornelis Boersma, Vera H.M. Deneer, Jurriën M. ten Berg	378
7	Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome 2019 ·Coronary Artery Disease ·Marieke E. Gimbel, Gerrit J.A. Vos, (unknown), Johannes C. Kelder, Jurriën M. ten Berg	6
8	Feasibility and Implementation of CYP2C19 Genotyping in Patients Using Antiplatelet Therapy 2018 ·Pharmacogenomics ·Thomas O. Bergmeijer, Gerrit J.A. Vos, Daniel M.F. Claassens, Paul W.A. Janssen, (unknown), (unknown), Folkert W. Asselbergs, Jurriën M. ten Berg, Vera H.M. Deneer	20
9	Management of the patient with an acute coronary syndrome using oral anticoagulation 2015 ·Netherlands Heart Journal ·Gerrit J.A. Vos, (unknown), (unknown), Jurriën M. ten Berg	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact